AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04826341
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab Govitecan will be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles.
Trial: NCT01169792
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03586089
Drug: Phenobarbital Sodium
RxNorm normalized name: Phenobarbital Sodium
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
Trial: NCT06031558
Drug: SY-5007
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a RET selective Inhibitor
Trial: NCT05943041
Drug: GB104(Level 1)
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule QD oral administration for 28 days
Trial: NCT05943041
Drug: GB104(Level 2)
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three capsules QD oral administration for 28 days
Trial: NCT05943041
Drug: GB104(Level 3)
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five capsules QD oral administration for 28 days
Trial: NCT06775041
Drug: Progerinin
RxNorm normalized name: Progerinin
DrugBank: Progerinin (DB17634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.
Trial: NCT06775041
Drug: Lonafarnib
RxNorm normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
Trial: NCT06770088
Drug: vnacicizumab
RxNorm normalized name: Vanucizumab
DrugBank: Vanucizumab (DB12317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.
Trial: NCT06775093
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 months
Trial: NCT06774261
Drug: Phenserine
RxNorm normalized name: Phenserine
DrugBank: Phenserine (DB04892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenserine is a next generation AChE inhibitor being developed for the treatment of AD. Unlike currently marketed AChE inhibitors, it has additional mechanisms of action that also include a mediating effect on cell death pathways and anti-amyloid activity, which may confer disease-modifying effects in people with AD.~Phenserine was originally identified and developed by the United States (U.S.) National Institute of Aging (NIA), part of the U.S National Institute of Health (NIH).~The study intervention will be open label. No blinding will be performed. Participants and site staff will, however, will be blinded to the results of the exosome and blood/CSF biomarker evaluations until the study is completed.
Trial: NCT06774261
Drug: Donepezil (Aricept®)
RxNorm normalized name: donepezil Oral Tablet [Aricept]
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The substance donepezil (under the brand name Aricept®) is a resale product. No additional manufacturing or labeling measures is necessary for this study.~The NIMP, donepezil will be available in 5 mg and 10 mg strengths (table 3) and will be dispensed by the local pharmacy at the hospital where the participant in the donepezil arm is included. We have based the use of donepezil as a treatment in the study on the original product from Pfizer, but it is also possible to use generic products of donepezil if this is what the local pharmacy has for dispensing. Participants randomized to treatment with donepezil will follow the treatment plan according to the patient information leaflet. . These tablets are approved for clinical use and comply with all relevant safety and efficacy standards.
Trial: NCT06770569
Drug: HRS-3802
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-3802
Trial: NCT06771050
Drug: Antibiotic duration Part A - Single stage revision
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Arm: Short course 6-week (42 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.~Intervention Arm: Long course 12- week (84 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.
Trial: NCT06772610
Drug: Ensartinib group
RxNorm normalized name: Streptococcus viridans group
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.
Trial: NCT06770426
Drug: phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Trial: NCT06771063
Drug: fluconazole capsules/placebo
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer fluconazole capsules/placebo orally
Trial: NCT06774222
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks
Trial: NCT06771609
Drug: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
RxNorm normalized name: Adbry
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Trial: NCT06771609
Drug: debry single antibody + VEX metronomic chemotherapy
RxNorm normalized name: digoxin antibodies Fab fragments
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
Trial: NCT06759610
Drug: Tetracyclin
RxNorm normalized name: Tetracyclin
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to evaluate the effect of tetracycline socked pack on acceleration of healing during marsupialization as a primary treatment for locally invasive lesions.
Trial: NCT06762119
Drug: CAR-T cell
RxNorm normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cell
Trial: NCT06760156
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The recommended dose of tafasitamab is 12 mg/kg.
Trial: NCT06760156
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The starting dose for lenalidomide will be 25 mg PO daily.
Trial: NCT05210192
Drug: Lidocaine Hydrochloride 1% Solution for Injection_#2
RxNorm normalized name: Lidocaine Hydrochloride 1% Solution for injection_#2
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.
Trial: NCT05573958
Drug: Rivaroxaban 2.5 Mg Oral Tablet
RxNorm normalized name: rivaroxaban 2.5 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 2.5 mg oral tablet will be administered twice daily
Trial: NCT05573958
Drug: Clopidogrel tablet
RxNorm normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 75 mg once daily orally
Trial: NCT05573958
Drug: Aspirin tablet
RxNorm normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg tablet once daily
Trial: NCT04873570
Drug: Moxifloxacin 400mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400mg IR tablet
Trial: NCT06666491
Drug: Tafenoquine
RxNorm normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of TQ will be administered orally on Day 1 or Day 2.
Trial: NCT06666491
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).
Trial: NCT06666491
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of CQ will be administered orally, daily, on Days 1 to 3.
Trial: NCT06669650
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxycodone
Trial: NCT06669650
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydromorphone
Trial: NCT06767046
Drug: KRAS-specific Autologous TCR-T cell injection
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
Trial: NCT06769971
Drug: Ivonescimab
RxNorm normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg，IV infusion，Day1，Q3W
Trial: NCT06769971
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg，IV infusion，Day8，Q6W
Trial: NCT06769971
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/kg，IV infusion，Day1-3，Q3W
Trial: NCT06769971
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5，IV infusion，Day1，Q3W
Trial: NCT06763783
Drug: Shingrix
RxNorm normalized name: Shingrix
DrugBank: Varicella zoster vaccine (recombinant) (DB13924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all participants vaccinates with two doses of Shingrix vaccine
Trial: NCT06763783
Drug: vaccination with 2 doses of Shingrix vaccine
RxNorm normalized name: varicella zoster virus glycoprotein E
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
Trial: NCT06781125
Drug: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions.
Trial: NCT06669143
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg bid, po, day 1-21, a maximum of 2 years.
Trial: NCT06669143
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg qd, po, day 1-10, a maximum of 2 years.
Trial: NCT06780930
Drug: Vorasidenib
RxNorm normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT04307615
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen: 20 min treatment followed by 10 min rest and assessment
Trial: NCT05673785
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin IV infusion
Trial: NCT05673785
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone tablets
Trial: NCT05904028
Drug: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
RxNorm normalized name: faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
Trial: NCT06334016
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vape active nicotine
Trial: NCT06094881
Drug: Obinutuzumab Injection [Gazyva]
RxNorm normalized name: obinutuzumab Injection [Gazyva]
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment.
Trial: NCT06509191
Drug: Intervention 2
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melatonin 8 mg/day
Trial: NCT04100135
Drug: Thienopyridine (clopidogrel or prasugrel)
RxNorm normalized name: Phenopyridine
DrugBank: Oxyquinoline (DB11145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Trial: NCT06772558
Drug: Desflurane Inhalation
RxNorm normalized name: Desflurane Inhalation Liquid
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
Trial: NCT06591468
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 30-40 mg/day, at 7am in the morning, gradually reduced after 1 month (5mg every 7-14 days) to 5-10 mg for maintenance treatment
Trial: NCT06591468
Drug: UDCA (Ursodeoxycholic acid)
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-15 mg/kg/day
Trial: NCT05271409
Drug: Satralizumab
RxNorm normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
Trial: NCT06793761
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg, IV, 3 cycles
Trial: NCT06793761
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 75mg/m2, IV, 3 cycles
Trial: NCT06793761
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 260mg, IV, 3 cycles
Trial: NCT05546268
Drug: Oral MRT-2359
RxNorm normalized name: monofluorophosphate
DrugBank: MRT-2359 (DB18015)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered tablets of MRT-2359.
Trial: NCT05546268
Drug: Oral MRT-2359
RxNorm normalized name: monofluorophosphate
DrugBank: MRT-2359 (DB18015)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
Trial: NCT05546268
Drug: Oral MRT-2359
RxNorm normalized name: monofluorophosphate
DrugBank: MRT-2359 (DB18015)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
Trial: NCT06772324
Drug: NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.
Trial: NCT06772324
Drug: NORSPAN Buprenorphine Transdermal Patchs for Lower dose group
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.
Trial: NCT06772324
Drug: NORSPAN Buprenorphine Transdermal Patchs for higher dose group
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.
Trial: NCT06140290
Drug: Etrasimod Immediate Release (IR)
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An immediate release tablet
Trial: NCT05493501
Drug: Aumolertinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
Trial: NCT05493501
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
Trial: NCT05493501
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Trial: NCT05556746
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily therapy for 12 weeks
Trial: NCT05556746
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily therapy for 12 weeks
Trial: NCT05556746
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily therapy for 12 weeks
Trial: NCT05556746
Drug: Delamanid
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Daily therapy for 12 weeks
Trial: NCT05556746
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily therapy for 26 weeks
Trial: NCT05556746
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily therapy for 26 weeks
Trial: NCT05556746
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily therapy for 8 weeks
Trial: NCT05556746
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily therapy for 8 weeks
Trial: NCT05493501
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Trial: NCT05493501
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
Trial: NCT05493501
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by IV Infusion given over 4 fixed cycles per prescribing information.